KennethCarlAndersonMD

Oncology • Boston, MA

Hematologic Oncology

Kraft Family Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Anderson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Anderson's full profile

Already have an account?

Office
440 Binney St
Dana Farber Cancer Institute
Boston, MA 02115
Phone+1 617-632-2144

Fax+1 617-632-2140

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 1977 - 1980
Johns Hopkins University School of MedicineClass of 1977

Certifications & Licensure

MA State Medical License 1980 - 2025
MD State Medical License 1977 - 1980
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Elected Member Institute of Medicine, 2010
Elected Member The American Society for Clinical Investigation, 1996
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma Start of enrollment: 1994 Jan 01
Completed
Phase 3
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2001 Nov 01
Completed
Phase 2
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Start of enrollment: 2004 Dec 15
Active, not recruiting
Phase 3
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Aug 01
Completed
Phase 1
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Aug 01
Completed
Phase 1, Phase 2
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Start of enrollment: 2012 Jul 03
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma ce...
Constantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, Robert Schlossman, Masaharu Akiyama
Oncogene. 2025-02-01
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.
Johannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, Tushara Vijaykumar, Praveen Anand
Blood Advances. 2025-01-15
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
Omar Nadeem, Michelle P Aranha, Robert Redd, Michael Timonian, Sophie Magidson
Nature Communications. 2025-01-03

Journal Articles

APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic Implications
Kenneth C Anderson, Nikhil Munshi, Paul Richardson, Chirag Acharya, Nature
Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma
Nikhil Munshi, Kenneth C Anderson, A Keith Stewart, Sagar Lonial, Blood

Abstracts/Posters

Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High-Dimensional Heterogeneity of Waldenstr_m Macroglobulinemia within Its Immune Tumor Microenvironment
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
TNF-_ Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Timing the Initiation of Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma
Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Blood and Beyond: Cancer- what it does to you AND for you
60th American Society of Hematology Annual Meeting - 12/2/2018
Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse
60th American Society of Hematology Annual Meeting - 12/1/2018

Press Mentions

Immunotherapeutic and Targeted Approaches in Multiple MyelomaOctober 14th, 2020
With Meetings Banned, Millions Struggle to Stay Sober on Their OwnMarch 26th, 2020
Physicians’ Education Resource® Presents the 3rd Annual Live Medical Crossfire®: Hematologic MalignanciesJune 20th, 2019
Join now to see all

Grant Support

Targeting Myeloma Cell-Host Bone Marrow InteractionsNational Cancer Institute2010–2012
Host-Tumor Cell Interaction In Myeloma: Therapeutic ApplicationsNational Cancer Institute2010–2012
Administrative And Clinical SupportNational Cancer Institute2010–2012
Molecular Sequelae Of Myeloma-Bone Marrow Interactions: Therapeutic ApplicationsNational Cancer Institute2009–2012
Spore In MyelomaNational Cancer Institute2008–2011
P-1: Proteosome-Directed Novel Myeloma TherapiesNational Cancer Institute2008–2011
Developmental Research ProgramNational Cancer Institute2008–2011
Career Development ProgramNational Cancer Institute2008–2011
CA: Administration CoreNational Cancer Institute2008–2011
Host-Tumor Cell Interactions In Myeloma: Therapeutic ApplicationsNational Cancer Institute2007–2009
Host-Tumor Cell Interactions In Myeloma:National Cancer Institute2004–2008
Specialized Program Of Research Excellence In MyelomaNational Cancer Institute2003–2007
Role Of Cytokines In Myeloma PathogenesisNational Cancer Institute2003–2007
Host-Tumor Cell Interactions In Myeloma Therapeutic APPLNational Cancer Institute2003
Novel Immune Based Therapies For Multiple MyelomaNational Cancer Institute1998–2002
KSHV And Vil6 In The Pathogenesis Of Multiple MyelomaNational Cancer Institute1998–2002
Allogeneic Graft-Vs-Myeloma Immunity After Stem Cell TransplantationNational Cancer Institute1998–2002
Regulation Of Interleukin 6 In Multiple MyelomaNational Cancer Institute1995–1997
Characterization Of Growth Factor Responsive B CellsNational Cancer Institute1991–1993